The antitumor activity of osimertinib plus palbociclib in non-small cell lung cancer patient-derived xenograft (PDX)/2D/3D culture models harboring EGFR amplification and CDKN2A/2B homozygous deletions

Jen Fen Fu*, Cheng Lung Hsu*, Ping Chih Hsu*

*Corresponding author for this work

Research output: Contribution to journal › Journal Article › peer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'The antitumor activity of osimertinib plus palbociclib in non-small cell lung cancer patient-derived xenograft (PDX)/2D/3D culture models harboring EGFR amplification and CDKN2A/2B homozygous deletions'. Together they form a unique fingerprint.

Biochemistry, Genetics and Molecular Biology